Jump to content

Property:Exclusion criteria

From CAMIH

This is a property of type Text.

Showing 20 pages using this property.
R
Had known metastatic disease to the bone, kidney stones, primary hyperparathyroidism, Paget’s disease of the bone, severe arthritis, rheumatoid arthritis, severe neuropathy or 25OHD C 30 ng/ml; treatment on the trial was stopped if the patient developed hypercalciuria (C250 mg/g creatinine) or hypercalcemia (C10.3 mg/dl)  +
With liver, kidney, or chronic inflammatory autoimmune diseases; with active infectious diseases; who were undergoing therapy with immunosuppressants; who were on vitamin or mineral supplementation; who had been on chemo- or radiation therapy in the previous 12 months; and who had been diagnosed as cognitively impaired  +
Demolitive surgery of the tongue, palate, or oropharynx; the presence of oral lesions, such as stomatitis, ulcers, necrosis, or candidiasis; complete or full upper dentures; elimination of the olfactory component of taste after laryngectomy; concomitant administration of chemotherapy and or any other kind of drug affecting taste; lesions of cranial nerves V, VII, IX, or X; damage to the nervous system after surgery or cerebral lesions; metabolic alterations or disorders; endocrine or neurologic diseases known to influence taste and/or smell sensitivity; local disease in the nose or ears; and lack of cooperation on the part of patients  +
Patients on coumadin or heparin for therapeutic anticoagulation, patients with a bleeding disorder, patients who hadn't had platelet count >100,000/μl before the baseline cycle  +
Patients who: had bilateral breast cancer; previous radiation to the chest or breast area; diagnosis of inflammatory breast cancer; breast reconstruction and/or expanders prior to RT; were taking anti-coagulant therapy (warfarin, coumadin or heparin) or antiepidermal growth factor receptor (EGFR) therapy or were receiving partial breast irradiations  +
S
Radiotherapy in the past year; food allergy; hypersensitivity to benzydamine, NSAIDs, or aloe; existing lesions in the oral cavity  +
Active infection; other causes of haematochezia including bowel cancer; IBD; haemorrhoids; anal incontinence; anorectal fistula; anorectal stenosis; previous rectal surgery; pregnant or breastfeeding women; women of childbearing age without appropriate contraception; allergy to components of the ointments tested; use of antibiotics or steroids  +
Previous history of peripheral neuropathy or symptomatic peripheral neuropathy at entry into the study, received other chemotherapy regimens, currently receiving anticoagulants, platelet aggregation inhibitors, opioids, anticonvulsants, tricyclic antidepressants, and previous history of hemorrhagic stroke  +
Women with other malignancies, allergies to ginger, perfumes or cosmetics or who were undergoing concurrent radiotherapy  +
Patients with multiple-day chemotherapy; receiving concurrent radiotherapy with high risk of causing emesis (i.e., total body, hemi body, upper abdomen, and craniospinal radiation); taking therapeutic doses of warfarin, aspirin, or heparin; had a history of bleeding disorder(s) like severe thrombocytopenia; had an allergy to ginger or chamomile or had taken it in the last week; had gastrointestinal disorders and cancers; and had other emesis-inducing diseases, such as hypertension, liver, and renal failure. Further exclusion of patients who met the following criteria: forgotten to take capsules ≥3 consecutive times; used other antiemetic drugs or therapeutic methods except the routine antiemetic; had severe gastrointestinal problems during the study; and refusal to continue participating in trial.  +
Previously diagnosed with cancer, had other concomitant cancers, distant metastases or recurrent cancer, had undergone prior radiation therapy or chemotherapy, or had received drug containing zinc  +
A previous diagnosis of cancer, a concomitant cancer, distant metastases or recurrent cancer, prior radiation therapy or chemotherapy, pregnancy, an autoimmune disease, or drugs received that contained zinc  +
Prior cytotoxic chemotherapy (except estramustine monotherapy), bone-seeking radioisotope therapy, prior untreated CNS involvement, or malignancy other than prostate cancer (except adequately treated basal or squamous cell skin cancer or any other cancer from which the individual had been disease free for > 5 years), history of hypercalcemia or vitamin D toxicity, active uncontrolled infection, symptomatic peripheral neuropathy of grade > 2, or hypersensitivity to any treatment component; use of calcium supplements higher than 500 mg and pharmacologic doses of vitamin D or its derivatives (> 400 U or 10 μg)  +
History of peripheral neuropathy and systemic diseases such as diabetes mellitus, systemic lupus erythematosus, HIV, and alcohol problems, as well as those with a history of chemotherapy treatment  +
Received previous aromatase inhibitor treatment, had a history of rheumatoid arthritis, hypercalcemia or were taking excluded medications, unwilling to discontinue other oral supplements containing D3 and/or calcium; patients with osteoporosis in some cases  +
History of cancer (excluding basal cell carcinoma), participating in another clinical trial and clinically significant cognitive impairment or dementia.  +
The exclusion criteria included allergy to ginger, history of chemotherapy, history of other malignancy in women, reception of vitamin E and omega-3 before or concurrent with chemotherapy, chemotherapy intolerance and patients with stage 4 ovarian cancer.  +
Being pregnant, diabetes, asthma, Sjogren's syndrome, lack of ability to feed by mouth, using anti-depressant medications, a history of allergy to ginger or corn starch and people who have had recurrence of cancer and residence outside the city of Ahvaz and the lack of consent of the participation in the study.  +